Ki20227
CAS No. 623142-96-1
Ki20227( Ki 20227 | Ki-20227 )
Catalog No. M15358 CAS No. 623142-96-1
A potent, selective, orally active c-Fms inhibitor with IC50 of 2 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 50 | In Stock |
|
| 5MG | 87 | In Stock |
|
| 10MG | 147 | In Stock |
|
| 25MG | 284 | In Stock |
|
| 50MG | 507 | In Stock |
|
| 100MG | 707 | In Stock |
|
| 500MG | 1431 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKi20227
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, orally active c-Fms inhibitor with IC50 of 2 nM.
-
DescriptionA potent, selective, orally active c-Fms inhibitor with IC50 of 2 nM; weakly inhibits KDR, c-Kit, and PDGFRβ with IC50 of 12, 451, and 217 nM, respectively, no activty against Flt-3, c-Src, Fyn, EGFR, FGFR2, Met, Btk, PKA, and PKCα (IC50>1,000 nM); inhibits the M-CSF-dependent cell growth, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
-
In VitroKi20227 (0.1-1000 nM; 72 hours) with 100 and 1,000 nM almost suppresses M-NFS-60 cell growth and HUVEC cell growth, respectively. Ki20227 (0.1-1000 nM; 1 hour) suppresses M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner. Cell Viability Assay Cell Line:M-NFS-60 cells, HUVEC cells, human A375 melanoma cells Concentration:0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM Incubation Time:72 hours Result:100 and 1,000 nM almost suppressed M-NFS-60 cell growth and HUVEC cell growth, respectively.Cell Viability Assay Cell Line:RAW264.7 cell lysate Concentration:0.1, 0.3, 1, 3, 10, 30, 100, 300, 1000 nM Incubation Time:1 hourResult:Suppressed M-CSF-dependent c-Fms phosphorylation in a dose-dependent manner.
-
In VivoKi20227 (orally;10-50 mg/kg/d for 20 days) of 50 mg/kg/d of Ki20227 for 20 days markedly decreases the osteolytic lesion areas. ki20227 during global ischemia led to a significant deficit in microglial density in the CNS in mice, and CSF1R-inhibition led to a significant reduction in the neuronal density of mice. Animal Model:4-week-old male F344/NJcl-rnu rats.Dosage:10, 20, and 50 mg/kg Administration:Orally; once per day for 20 days Result:Oral administration of 50 mg/kg/d markedly decreased the osteolytic lesion areas.
-
SynonymsKi 20227 | Ki-20227
-
PathwayTyrosine Kinase
-
TargetCSF1R
-
RecptorCSF-1R,VEGFR2
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number623142-96-1
-
Formula Weight480.5362
-
Molecular FormulaC24H24N4O5S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 7.2 mg/mL
-
SMILESO=C(NC(C1=NC=CS1)C)NC2=CC=C(OC3=CC=NC4=CC(OC)=C(OC)C=C34)C=C2OC
-
Chemical NameUrea, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-methoxyphenyl]-N'-[1-(2-thiazolyl)ethyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ohno H, et al. Mol Cancer Ther. 2006 Nov;5(11):2634-43.
2. Ohno H, et al. Eur J Immunol. 2008 Jan;38(1):283-91.
3. Uemura Y, et al. J Neuroimmunol. 2008 Mar;195(1-2):73-80.
molnova catalog
related products
-
cFMS Receptor Inhibi...
cFMS Receptor Inhibitor II is a?CSF1R?kinase inhibitor.
-
JNJ-6204
JNJ-6204 is a dual inhibitor of CSNK1D (IC50 = 2.3 nM) and CSNK1E (IC50 = 137 nM).
-
Mavrilimumab
Mavrilimumab (CAM 3001) is a monoclonal antibody with antiviral activity that targets the α subunit of the granulocytic-macrophage colony-stimulating factor (GM-CSF) receptor, inhibiting downstream intracellular GM-CSF signaling.
Cart
sales@molnova.com